Nektar Therapeutics – Knox Daily

Stock Earnings

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or

Analysts Viewpoint

In a filing, Nektar Therapeutics revealed its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $8788.0 on Aug

Analysts Viewpoint

Nektar Therapeutics’s recent filing unveils that its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $8788.0 on Aug

Stock Earnings

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its

Analysts Viewpoint

Nektar Therapeutics’s recently made public that its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $8788.0 on Aug

Stock Earnings

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or

Analysts Viewpoint

Nektar Therapeutics’s recent filing unveils that its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $8788.0 on Aug

Stock Earnings

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its

Analysts Viewpoint

Nektar Therapeutics’s filing revealed that its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $8788.0 on Aug 19

Insiders Updates

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or

Tag: Nektar Therapeutics